Document ID: chunk:federal_register_of_legislation:F2025C00119:clause:3_1:p6
Version: federal_register_of_legislation:F2025C00119
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 6/69)
Character Range: 209246–218951

emetogenic cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                The treatment must be in combination with a 5‑hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle; AND
                                                                                                                Patient must have had a prior episode of chemotherapy induced nausea or vomiting; AND
                                                                                                                Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; raltitrexed.
                                                                                                                No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.
                                                                                                                Concomitant use of a 5HT3 antagonist should not occur with fosaprepitant on days 2 and 3 of any chemotherapy cycle.
C6891                              Fosaprepitant                                                                Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures ‑ Streamlined Authority Code 6891
                                                                                                                The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer; AND
                                                                                                                The treatment must be in combination with a 5‑hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                Patient must be scheduled to be co‑administered cyclophosphamide and an anthracycline.
                                                                                                                No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.
C7258               P7258          Eribulin                                                                     Advanced (unresectable and/or metastatic) liposarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures ‑ Streamlined Authority Code 7258
                                                                                                                Initial treatment
                                                                                                                Patient must have an ECOG performance status of 2 or less; AND
                                                                                                                The condition must be dedifferentiated, myxoid, round‑cell or pleomorphic subtype; AND
                                                                                                                Patient must have received prior chemotherapy treatment including an anthracycline and ifosfamide (unless contraindicated) for this condition; AND
                                                                                                                The treatment must be the sole PBS‑subsidised therapy for this condition.
                                                                                                                Patient must be aged 18 years or older.
C7280               P7280          Eribulin                                                                     Advanced (unresectable and/or metastatic) liposarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures ‑ Streamlined Authority Code 7280
                                                                                                                Continuing treatment
                                                                                                                Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                Patient must not develop progressive disease while being treated with this drug for this condition; AND
                                                                                                                The treatment must be the sole PBS‑subsidised therapy for this condition.
                                                                                                                Patient must be aged 18 years or older.
C7526               P7526          Pralatrexate                                                                 Relapsed or chemotherapy refractory Peripheral T‑cell Lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures
                                                                                                                Continuing treatment
                                                                                                                The condition must be relapsed or chemotherapy refractory; AND
                                                                                                                Patient must not develop progressive disease whilst receiving PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                Patient must have previously received PBS‑subsidised treatment with this drug for this condition.
C7558               P7558          Pralatrexate                                                                 Relapsed or chemotherapy refractory Peripheral T‑cell Lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required